Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ESMO WCGC 2013 Report – When is neoadjuvant chemotherapy (without radiotherapy) an option

Written by | 20 Sep 2013

A review of the presentation by Professor David Cunningham (pictured), London, UK.  The risk profile of rectal tumours varies with the position and profile of the disease. David… read more.

ESMO WCGC 2013 Report – OS though not PFS superior for FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in mCRC patients: Findings from FIRE-3

Written by | 19 Sep 2013

Dominik Modest, University Hospital, Grosshadern, Munch, Germany.  Overall survival (OS) in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) who received first-line treatment with FOLFIRI plus… read more.

ESMO WCGC 2013 Report – First results of the PETACC-6 phase III RCT

Written by | 18 Sep 2013

Review of the presentation by HJ Schmoll EORTC GI Group.  [Preoperative chemoradiotherapy with capecitabine and oxaliplatin vs capecitabine alone in locally advanced rectal cancer: response to the local treatment… read more.

ESMO WCGC 2013 Report – Surgery for Liver Metastases: How far should the surgeon go?

Written by | 18 Sep 2013

A review of the presentation by Rene Adam MD (pictured).  There has been considerable progress in the overall survival of patients with colorectal cancer taking chemotherapy.

ESMO WCGC 2013 Report – Hot topics in Colon Cancer

Written by | 12 Sep 2013

by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.

ESMO WCGC 2013 – Video Interview with Prof. Lenz

Written by | 11 Sep 2013

We ask Professor Heinz-Josef Lenz, Professor of Medicine, Associate Director Clinical Research what he thinks is going to be the next big thing in colorectal cancer for the… read more.

Green light for new medicines

Written by | 5 Sep 2013

EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has a new member: Ivana Mikacic has been nominated by Croatia which… read more.

Chemotherapy-refractory large B-cell lymphomas reprogrammed to respond to Azacitidine

Written by | 29 Aug 2013

FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.

BPA linked to birth defect in boys

Written by | 22 Aug 2013

A new study links fetal exposure to a common chemical pollutant, bisphenol A (BPA), to defects of a testicular hormone in newborn boys with undescended testicles. The results… read more.

ASCO Interview 2013: Matthias Holdhoff discusses his presentation on primary CNS lymphoma

Written by | 25 Jul 2013

Matthias Holdhoff, MD, PHD, Assistant Professor of Oncology.  The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ASCO Interview 2013: Dr Erin Dunbar shares her thoughts about the presentation on Ethics of Cancer Care

Written by | 25 Jul 2013

Dr Erin Dunbar, Assistant Professor and Co. Director, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Department of Neurosurgery, University of Florida.

ASCO Interview 2013: Dr Brian Healey Bird gives us his feedback on the Lung Cancer Education Session at ASCO

Written by | 25 Jul 2013

Dr Brian Healey Bird FCPI.  Consultant Medical Oncologist, Bon Secours Cork.  Senior Clinical Lecturer, University College Cork.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.